The approval is supported by a prespecified interim analysis from the ongoing, randomised Phase III ALIGN trial.

The U.S. Food and Drug Administration (FDA) on Wednesday granted accelerated approval for Novartis AG’s (NYSE:NVS) Vanrafia ...

The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ® (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid ...

Novartis is uniquely positioned to lead a transformation in kidney care Vanrafia was granted accelerated approval based on a prespecified interim analysis of the Phase III ALIGN study measuring ...

Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US ...

Novartis ( NYSE: NVS) said on Thursday that it received US FDA's accelerated approval for Vanrafia as a treatment for adults ...

Novartis has received accelerated approval from the US Food and Drug Administration (FDA) for Vanrafia (atrasentan), a potent ...

Swiss pharma giant Novartis (NOVN: VX) today announced the US Food and Drug Administration (FDA) has granted accelerated ...

Novartis (NVS) “announced the FDA has granted accelerated approval for Vanrafia, or atrasentan, a potent and selective endothelin A receptor ...

(RTTNews) - Novartis (NVS) announced that the US Food and Drug Administration has granted accelerated approval for Vanrafia or atrasentan, a potent and selective endothelin A (ETA) receptor ...